Achieving Sustainability

Healthcare: how to live better

Many of us embrace the idea of living to a ripe old age. Yet the resources required to sustain longer lifespans are a growing financial burden. While provision and funding of health services varies around the world, the growing pressures on the delivery of adequate care are almost universal – as is the need for long-term investment into the sector.

Key takeaways
  • Ageing populations with multiple illnesses are set to increase medical costs, with healthcare spending already close to 10% of GDP for many countries.
  • Emerging health issues caused by climate impacts will add pressure to health budgets.
  • Investors can contribute to the positive societal and economic outcomes of improved health by directing capital to target new solutions.
  • Our ReCLAIM health model identifies the sector’s risks and investment opportunities.

Improvements in public health, nutrition and medicine in recent decades mean many of us are living longer, but are we living better? Life expectancy increased by almost six years between 2000-2019,1 but failing health in later life is driving up healthcare costs which already account for almost 10% of GDP in OECD countries.2 Ageing populations and lifestyle changes are set to add to this financial burden. Additionally, climate impacts affecting health – for example, excess temperatures and exposure to unclean flood waters – will reveal new costs.

The price of living longer

Healthcare has seen inflation pressures equivalent to those of energy and food in recent years.3 Despite pharmaceutical pricing making headlines, hospital care is the single largest cost, encompassing medical facilities, staff salaries, equipment, and patient care. Hospital resources will see greater demand for those with later life and lifestyle-related health issues. In the US – the largest single spender on health – more patients will depend on the 30% of its health budget already allocated to hospitals.

Exhibit 1: Hospital costs are draining healthcare budgets
Exhibit 1: Hospital costs are draining healthcare budgets

Source: American Medical Association, Trends in health care spending | Healthcare costs in the US | AMA (ama-assn.org), April 2024

Rising costs can translate into rising additional patient payments, further increasing “catastrophic health expenditure”. This is defined as 10% of household income spent on health4 and currently applies to approximately 12% of the global population – over 800 million people. Moreover, patients face a further hike of more than 3% annually in these costs. The impact on patients of these spiralling costs varies with the differing models of medical care funding around the world. These models can be grouped into three broad categories: taxation, private health insurance, and social health insurance. Additionally, in some countries health is a pure out-of-pocket expense.

Exhibit 2: Health costs per capita by country in 2022
Exhibit 2: Health costs per capita by country in 2022

Source: OECD, Health at a Glance 2023, November 2023

What is universally true is that health costs ramp up for end-of-life services because living longer means more years spent in ill health – see Exhibit 3. For US federal medical insurance programme, Medicare, 25% of annual spend goes to 5% of patients in the last year of their lives.5

Exhibit 3: Longer lives are increasing years of ill health
Exhibit 3: Longer lives are increasing years of ill health

Source: WEF, Transforming Healthcare: Navigating Digital Health with a Value-Driven Approach, January 2024

Getting what you paid for?

These rising costs further contribute to the significant inequality in medical care with half of the global population lacking access to essential health services.

Additionally, strained healthcare budgets bring the challenges of limited drug choice, high patient waiting times and restricted availability of nonemergency procedures and operations.

There is also a worrying economic impact in lost productivity for workers in poor health. This reduced labour market participation and income can drive additional mental and physical health issues.6

ReCLAIMing better health

How can investment drive better health? We have developed a model to simplify the wide-ranging scope of health issues. Our ReCLAIM model7 identifies six broad areas where we see risks and outline opportunities to finance a healthier future.

Exhibit 4: Our ReCLAIM model of healthcare risks and opportunities
Exhibit 4: Our ReCLAIM model of healthcare risks and opportunities

Source: Allianz Global Investors, May 2024

ReCLAIM model: six key health issues to address

1. Resistance
Antimicrobial resistance has emerged as a major global public health threat. It occurs when bacteria and other microorganisms evolve to evade the effects of antibiotics and other antimicrobial treatments.9 Treating infections can become difficult or even impossible and increases the risk of disease spread, severe illness, disability, and death.

In April 2024, the World Health Organization (WHO) highlighted the potential for the H5N1 strain of bird flu to spread to other species, including humans. This follows reported human infections10 and particles of the virus being found in cow’s milk sold in US stores.11 The WHO has already warned any new pandemic could be a flu virus and Covid-19 starkly highlighted the cost and time required to develop antidotes to such fast-spreading severe infections.

2. Climate change
The effects of heatwaves on the general population are already well-documented, with older age groups and those with underlying illnesses particularly at risk. The International Labor Organization also estimates that over 70% of the global workforce may be exposed to climate change-related health hazards with 1.6 billion outdoor workers continuously exposed to air pollution, extreme heat and UV radiation. These issues are linked to cardiovascular and respiratory conditions, and some cancers. Outdoor air pollution is a particular concern as hazard encapsulation12 and ventilation are not always applicable to outdoor environments giving employers and workers little or no control over sources of pollution.13 Existing occupational health and safety measures are struggling to keep pace with these escalating risks.

3. Lifestyle
Limited exercise and poor diets are increasing morbidity and burdening healthcare systems. Combined with ageing populations and an increase in long-term medical conditions means multimorbidity is set to rise.14 Multimorbidity refers to having two or more long-term medical conditions requiring more healthcare resources for complex care needs that are costly and challenging. This can mean more frequent hospital admissions, longer hospital stays and access to multiple medical specialists during a typical year.15

One example is Type 2 diabetes, which is linked to diet and weight issues and can cause blindness, heart disease and lower limb complications. This is a growing concern as approximately 1 in 8 people are considered obese, with the overweight population now surpassing the number who are underweight.

4. Affordability
Most European countries have achieved universal coverage of health care costs for a core set of services – consultations with doctors, tests and examinations, and hospital care. This gives patients some financial protection from unexpected costs.16 Nevertheless, the extent of healthcare coverage can vary and, while private insurance can accelerate access to healthcare services, additional costs often apply.

5. Infrastructure
Resilient infrastructure is needed to mitigate climate and physical health risks, to the extent that, during COP 26 in November 2021, a group of 50 countries committed to develop climate-resilient and low-carbon health systems in response to rising evidence of climate impact on health.17 Infrastructure priorities include sanitation, clean water, and energy security.

Furthermore, access to medical resources remains concentrated in urban areas where an estimated 56% of the population lives. With larger numbers expected to move out of cities public health investment in rural areas remains inadequate and a significant increase is required to support sizeable rural populations.18

6. Mental health
The Covid-19 pandemic brought greater recognition of the scale of poor mental health. This is increasingly linked to lower productivity and social care implications, with estimated costs of up to USD 14 billion annually in lost productivity, absenteeism, and employee turnover.19

Opportunities to invest in health

How does this translate into investment opportunities? We see strong potential for investment capital to drive improvements in delivery and access to better healthcare for all. There will be significant costs to mitigate these risks, but the economic benefits are also significant in terms of limiting the rise in costs relative to GDP, reducing health inequality (from both rising health costs and insurance premiums) and boosting productivity.

Preventing morbidity
Investing in research and development for innovative and effective medicine can help mitigate the healthcare burden. Such new treatments can target lifestyle-driven conditions, eg, Type 2 diabetes and morbidity, as well as cancers and mental health. This would also target environmental-change conditions like fevers and microbial infections. New curative drugs, eg, for hepatitis C are already available and gene therapies for rare diseases have been developed recently.  

Tackling climate impacts
The planet is getting hotter, and heat raises the risk of new diseases and virus infections migrating to previously unaffected countries.20 This requires development of vaccines to prevent severe diseases, such as dengue and West Nile fever, migrating to northern geographic areas. In addition, respiratory solutions will be in demand as hot, humid air can increase conditions like asthma and chronic obstructive pulmonary disease.

Embracing technology
The rapid rise in artificial intelligence (AI) capabilities is helping to accelerate drug discovery, enhance product quality, and cut costs of clinical trials, by early and efficient identification of key failure points in critical stages of drug analysis.21 New solutions need to be supported by equivalent improvements in healthcare access. Telemedicine is critical in improving access to care and diagnostics applicable across borders and in rural areas where it can be more cost efficient than traditional points of access.  

Improving infrastructure
Greater investment in healthcare infrastructure will be needed to adapt to higher heat and physical risks. Cooling plans, often developed by governments and municipalities, will require investment in hospitals to implement new infrastructure like improved air conditioning, while installing alternative electricity sources, eg, solar panels can mitigate energy-related physical risks.

It is clear that resetting current fractured health services must become a long-term priority for governments, investors and other stakeholders. It has famously been said that health is the greatest wealth. Preserving this wealth means directing capital towards solutions for a healthier future, supporting economic growth and driving social cohesion.

1 Source: WEF, Transforming Healthcare: Navigating Digital Health with a Value-Driven Approach, January 2024
2 Source: OECD, Health Statistics 2023 
3 Source: McKinsey & Company, The gatherting storm: transformative impact of inflation on the healthcare sector, September 2022 
4 Source: WHO, SDG 3.8.2 Catastrophic health spending (and related indicators), 2024 
5 Source: National Library of Medicine, Medicare cost at end of life, August 2019 
6 Source: OECD, Health at a glance: Europe 2016, 2016 
7 ReCLAIM is an acronym of Resistance, Climate Change, Lifestyle, Affordability, Infrastructure and Mental health, developed by Allianz Global Investors’ Research team 
8 An example of this is zoonoses which are diseases or infections that are naturally transmissible from vertebrate animals to humans, WHO, July 2020 
9 Source: WHO, Antimicrobial resistance, November 2023 
10 Source: WHO, Avian Influenza A(H5N1) – United States of America, April 2024 
11 Source: CDC, Current H5N1 Bird Flu Situation in Dairy Cows, July 2024 
12 Encapsulation is a remedial solution to help in the prevention of fibre release from hazardous fibrous materials 
13 Source: International Labour Organization, Climate change creates a ‘cocktail’ of serious health hazards for 70 per cent of the world’s workers, April 2024
14,15 Source: National Library of Medicine, Multimorbidity: What do we know? What should we do?, February 2017
16 Source: OECD, Population coverage for health care | Health at a Glance: Europe,2020 
17 Source: WHO, Countries commit to develop climate-smart health care at COP26 UN climate conference, November 2021 
18 Source: World Bank, Urban Development Overview, October 2022 
19 Source: Deloitte, 2023 Global Health Care Outlook, 2023 
20 Source: Allianz Global Investors, Health is wealth, October 2023 
21 Source: Allianz Global Investors, The healthcare industry is using AI to transform drug discovery, November 2023  

  • Disclaimer
    Investing involves risk. The value of an investment and the income from it will fluctuate and investors may not get back the principal invested. Past performance is not indicative of future performance. This is a marketing communication. It is for informational purposes only. This document does not constitute investment advice or a recommendation to buy, sell or hold any security and shall not be deemed an offer to sell or a solicitation of an offer to buy any security.

    The views and opinions expressed herein, which are subject to change without notice, are those of the issuer or its affiliated companies at the time of publication. Certain data used are derived from various sources believed to be reliable, but the accuracy or completeness of the data is not guaranteed and no liability is assumed for any direct or consequential losses arising from their use. The duplication, publication, extraction or transmission of the contents, irrespective of the form, is not permitted.

    This material has not been reviewed by any regulatory authorities. In mainland China, it is for Qualified Domestic Institutional Investors scheme pursuant to applicable rules and regulations and is for information purpose only. This document does not constitute a public offer by virtue of Act Number 26.831 of the Argentine Republic and General Resolution No. 622/2013 of the NSC. This communication's sole purpose is to inform and does not under any circumstance constitute promotion or publicity of Allianz Global Investors products and/or services in Colombia or to Colombian residents pursuant to part 4 of Decree 2555 of 2010. This communication does not in any way aim to directly or indirectly initiate the purchase of a product or the provision of a service offered by Allianz Global Investors. Via reception of this document, each resident in Colombia acknowledges and accepts to have contacted Allianz Global Investors via their own initiative and that the communication under no circumstances does not arise from any promotional or marketing activities carried out by Allianz Global Investors. Colombian residents accept that accessing any type of social network page of Allianz Global Investors is done under their own responsibility and initiative and are aware that they may access specific information on the products and services of Allianz Global Investors. This communication is strictly private and confidential and may not be reproduced, except for the case of explicit permission by Allianz Global Investors. This communication does not constitute a public offer of securities in Colombia pursuant to the public offer regulation set forth in Decree 2555 of 2010. This communication and the information provided herein should not be considered a solicitation or an offer by Allianz Global Investors or its affiliates to provide any financial products in Brazil, Panama, Peru, and Uruguay. In Australia, this material is presented by Allianz Global Investors Asia Pacific Limited (“AllianzGI AP”) and is intended for the use of investment consultants and other institutional /professional investors only, and is not directed to the public or individual retail investors. AllianzGI AP is not licensed to provide financial services to retail clients in Australia. AllianzGI AP is exempt from the requirement to hold an Australian Foreign Financial Service License under the Corporations Act 2001 (Cth) pursuant to ASIC Class Order (CO 03/1103) with respect to the provision of financial services to wholesale clients only. AllianzGI AP is licensed and regulated by Hong Kong Securities and Futures Commission under Hong Kong laws, which differ from Australian laws.

    This document is being distributed by the following Allianz Global Investors companies: Allianz Global Investors GmbH, an investment company in Germany, authorized by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin); Allianz Global Investors (Schweiz) AG; Allianz Global Investors UK Limited, authorized and regulated by the Financial Conduct Authority; in HK, by Allianz Global Investors Asia Pacific Ltd., licensed by the Hong Kong Securities and Futures Commission; in Singapore, by Allianz Global Investors Singapore Ltd., regulated by the Monetary Authority of Singapore [Company Registration No. 199907169Z]; in Japan, by Allianz Global Investors Japan Co., Ltd., registered in Japan as a Financial Instruments Business Operator [Registered No. The Director of Kanto Local Finance Bureau (Financial Instruments Business Operator), No. 424], Member of Japan Investment Advisers Association, the Investment Trust Association, Japan and Type II Financial Instruments Firms Association; in Taiwan, by Allianz Global Investors Taiwan Ltd., licensed by Financial Supervisory Commission in Taiwan; and in Indonesia, by PT. Allianz Global Investors Asset Management Indonesia licensed by Indonesia Financial Services Authority (OJK).

    3722510

Recent insights

Navigating Rates

With the potential for more frontloading of interest rate cuts by the European Central Bank, we see the possibility of further yield curve steepening, primarily from the more policy-anchored front end. In outright duration risk, we prefer to stay more tactical on US Treasuries.

Discover more

Navigating Rates

With all signs pointing to a Donald Trump win, we expect many of his populist policies to cause ripples, even though markets were largely priced for this outcome. How might investors navigate the election result?

DISCOVER MORE

Navigating Rates

All eyes will be on the US elections in November – but the implications for markets could be quite different depending on who wins.

Discover more

Allianz Global Investors

You are leaving this website and being re-directed to the below website. This does not imply any approval or endorsement of the information by Allianz Global Investors Asia Pacific Limited contained in the redirected website nor does Allianz Global Investors Asia Pacific Limited accept any responsibility or liability in connection with this hyperlink and the information contained herein. Please keep in mind that the redirected website may contain funds and strategies not authorized for offering to the public in your jurisdiction. Besides, please also take note on the redirected website’s terms and conditions, privacy and security policies, or other legal information. By clicking “Continue”, you confirm you acknowledge the details mentioned above and would like to continue accessing the redirected website. Please click “Stay here” if you have any concerns.

Welcome to Allianz Global Investors

Select your language
  • 中文(繁體)
  • English
Select your role
  • Individual Investor
  • Intermediaries
  • Other Investors
  • Pension Investors
  • Allianz Global Investors Fund (“AGIF”)

    • Allianz Global Investors Fund (“AGIF”) as an umbrella fund under the UCITS regulations has within it different sub-funds investing in fixed income securities, equities, and derivative instruments, each with a different investment objective and/or risk profile.

    • All sub-funds (“Sub-Funds”) may invest in financial derivative instruments (“FDI”) which may expose to higher leverage, counterparty, liquidity, valuation, volatility, market and over the counter transaction risks. A Sub-Fund’s net derivative exposure may be up to 50% of its NAV. 

    • Some Sub-Funds as part of their investments may invest in any one or a combination of the instruments such as fixed income securities, emerging market securities, and/or mortgage-backed securities, asset-backed securities, property-backed securities (especially REITs) and/or structured products and/or FDI, exposing to various potential risks (including leverage, counterparty, liquidity, valuation, volatility, market, fluctuations in the value of and the rental income received in respect of the underlying property, and over the counter transaction risks). 

    • Some Sub-Funds may invest in single countries or industry sectors (in particular small/mid cap companies) which may reduce risk diversification. Some Sub-Funds are exposed to significant risks which include investment/general market, country and region, emerging market (such as Mainland China), creditworthiness/credit rating/downgrading, default, asset allocation, interest rate, volatility and liquidity, counterparty, sovereign debt, valuation, credit rating agency, company-specific, currency  (in particular RMB), RMB debt securities and Mainland China tax risks. 

    • Some Sub-Funds may invest in convertible bonds, high-yield, non-investment grade investments and unrated securities that may subject to higher risks (include volatility, loss of principal and interest, creditworthiness and downgrading, default, interest rate, general market and liquidity risks) and therefore may adversely impact the net asset value of the Sub-Funds. Convertibles will be exposed prepayment risk, equity movement and greater volatility than straight bond investments.

    • Some Sub-Funds may invest a significant portion of the assets in interest-bearing securities issued or guaranteed by a non-investment grade sovereign issuer (e.g. Philippines) and is subject to higher risks of liquidity, credit, concentration and default of the sovereign issuer as well as greater volatility and higher risk profile that may result in significant losses to the investors. 

    • Some Sub-Funds may invest in European countries. The economic and financial difficulties in Europe may get worse and adversely affect the Sub-Funds (such as increased volatility, liquidity and currency risks associated with investments in Europe).

    • Some Sub-Funds may invest in the China A-Shares market, China B-Shares market and/or debt securities directly  via the Stock Connect or the China Interbank Bond Market or Bond Connect and or other foreign access regimes and/or other permitted means and/or indirectly through all eligible instruments the qualified foreign institutional investor program regime and thus is subject to the associated risks (including quota limitations, change in rule and regulations, repatriation of the Fund’s monies, trade restrictions, clearing and settlement, China market volatility and uncertainty, China market volatility and uncertainty, potential clearing and/or settlement difficulties and, change in economic, social and political policy in the PRC and taxation Mainland China tax risks).  Investing in RMB share classes is also exposed to RMB currency risks and adverse impact on the share classes due to currency depreciation.

    • Some Sub-Funds may adopt the following strategies, Sustainable and Responsible Investment Strategy, SDG-Aligned Strategy, Sustainability Key Performance Indicator Strategy (Relative), Green Bond Strategy, Multi Asset Sustainable Strategy, Sustainability Key Performance Indicator Strategy (Absolute Threshold), Environment, Social and Governance (“ESG”) Score Strategy, and Sustainability Key Performance Indicator Strategy (Absolute). The Sub-Funds may be exposed to sustainable investment risks relating to the strategies (such as foregoing opportunities to buy certain securities when it might otherwise be advantageous to do so, selling securities when it might be disadvantageous to do so, and/or relying on information and data from third party ESG research data providers and internal analyses which may be subjective, incomplete, inaccurate or unavailable and/or reducing risk diversifications compared to broadly based funds) which may result in the Sub-Fund being more volatile and have adverse impact on the performance of the Sub-Fund and consequently adversely affect an investor’s investment in the Sub-Fund. Also, some Sub-Funds may be particularly focusing on the GHG efficiency of the investee companies rather than their financial performance which may have an adverse impact on the Fund’s performance.

    • Some Sub-Funds may invest in share class with fixed distribution percentage (Class AMf). Investors should note that fixed distribution percentage is not guaranteed. The share class is not an alternative to fixed interest paying investment. The percentage of distributions paid by these share classes is unrelated to expected or past income or returns of these share classes or the Sub-Funds. Distribution will continue even the Sub-Fund has negative returns and may adversely impact the net asset value of the Sub-Fund.  Positive distribution yield does not imply positive return.

    • Investment involves risks that could result in loss of part or entire amount of investors’ investment.

    • In making investment decisions, investors should not rely solely on this [website/material].

    Note: Dividend payments may, at the sole discretion of the Investment Manager, be made out of the Sub-Fund’s capital or effectively out of the Sub-Fund’s capital which represents a return or withdrawal of part of the amount investors originally invested and/or capital gains attributable to the original investment. This may result in an immediate decrease in the NAV per share and the capital of the Sub-Fund available for investment in the future and capital growth may be reduced, in particular for hedged share classes for which the distribution amount and NAV of any hedged share classes (HSC) may be adversely affected by differences in the interests rates of the reference currency of the HSC and the base currency of the respective Sub-Fund. Dividend payments are applicable for Class A/AM/AMg/AMi/AMgi/AQ Dis (Annually/Monthly/Quarterly distribution) and for reference only but not guaranteed.  Positive distribution yield does not imply positive return. For details, please refer to the Sub-Fund’s distribution policy disclosed in the offering documents.

     


    Allianz Global Investors Asia Fund

    • Allianz Global Investors Asia Fund (the “Trust”) is an umbrella unit trust constituted under the laws of Hong Kong pursuant to the Trust Deed. Allianz Thematic Income and Allianz Selection Income and Growth and Allianz Yield Plus Fund are the sub-funds of the Trust (each a “Sub-Fund”) investing in fixed income securities, equities and derivative instrument, each with a different investment objective and/or risk profile.

    • Some Sub-Funds are exposed to significant risks which include investment/general market, company-specific, emerging market, creditworthiness/credit rating/downgrading, default, volatility and liquidity, valuation, sovereign debt, thematic concentration, thematic-based investment strategy, counterparty, interest rate changes, country and region, asset allocation risks and currency (such as exchange controls, in particular RMB), and the adverse impact on RMB share classes due to currency depreciation.  

    • Some Sub-Funds may invest in other underlying collective schemes and exchange traded funds. Investing in exchange traded funds may expose to additional risks such as passive investment, tracking error, underlying index, trading and termination. While investing in other underlying collective schemes (“CIS”) may subject to the risks associated to such CIS. 

    • Some Sub-Funds may invest in high-yield (non-investment grade and unrated) investments and/or convertible bonds which may subject to higher risks, such as volatility, creditworthiness, default, interest rate changes, general market and liquidity risks and therefore may  adversely impact the net asset value of the Fund. Convertibles may also expose to risks such as prepayment, equity movement, and greater volatility than straight bond investments.

    • All Sub-Funds may invest in financial derivative instruments (“FDI”) which may expose to higher leverage, counterparty, liquidity, valuation, volatility, market and over the counter transaction risks.  The use of derivatives may result in losses to the Sub-Funds which are greater than the amount originally invested. A Sub-Fund’s net derivative exposure may be up to 50% of its NAV.

    • These investments may involve risks that could result in loss of part or entire amount of investors’ investment.

    • In making investment decisions, investors should not rely solely on this website.

    Note: Dividend payments may, at the sole discretion of the Investment Manager, be made out of the Sub-Fund’s income and/or capital which in the latter case represents a return or withdrawal of part of the amount investors originally invested and/or capital gains attributable to the original investment. This may result in an immediate decrease in the NAV per distribution unit and the capital of the Sub-Fund available for investment in the future and capital growth may be reduced, in particular for hedged share classes for which the distribution amount and NAV of any hedged share classes (HSC) may be adversely affected by differences in the interests rates of the reference currency of the HSC and the base currency of the Sub-Fund. Dividend payments are applicable for Class A/AM/AMg/AMi/AMgi Dis (Annually/Monthly distribution) and for reference only but not guaranteed.  Positive distribution yield does not imply positive return. For details, please refer to the Sub-Fund’s distribution policy disclosed in the offering documents.

     

Please indicate you have read and understood the Important Notice.